Endocrinol Nutr. 2016;63(9):466---474 www.elsevier.es/endo ENDOCRINOLOGÍA Y NUTRICIÓN ORIGINAL ARTICLE Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia  Ana Maria Gomez a,* , Rafael Alfonso-Cristancho b,c , John Jairo Orozco d , Peter Matthew Lynch e , Diana Prieto b , Rhodri Saunders f , Stephane Roze g , Juan Esteban Valencia h a Hospital Universitario de San Ignacio --- Universidad Javeriana, Bogotá, Colombia b University of Washington, Seattle, WA, USA c RANDOM Foundation, Bogotá, Colombia d Medtronic PLC Andean Region, Bogotá, Colombia e Medtronic Diabetes Inc., Northridge, CA, USA f Ossian Health Economics and Communications, Basilea, Switzerland g HEVA HEOR, Lyon, France h Medtronic Latinamerica Inc., Miami, FL, USA Received 11 November 2015; accepted 31 May 2016 Available online 19 November 2016 KEYWORDS Type 1 diabetes; Insulin infusion systems; Continuous glucose monitoring; Cost-effectiveness analysis; Decision modeling Abstract Objective: To assess the long-term clinical and economic impact of integrated pump/CGM tech- nology therapy as compared to multiple daily injections (MDI), for the treatment of type 1 diabetes (T1D) in Colombia. Methods: The CORE Diabetes Model was used to simulate a hypothetical cohort of patients with T1D. Mean baseline characteristics were taken from a clinical study conducted in Colombia and a healthcare payer perspective was adopted, with a 5% annual discount rate applied to both costs and outcomes. Results: The integrated pump/CGM improved mean life expectancy by 3.51 years compared with MDI. A similar increase occurred in mean quality-adjusted life expectancy with an addi- tional 3.81 quality-adjusted life years (QALYs). Onset of diabetes-related complications was also delayed as compared to MDI, and mean survival time free of complication increased by  Please cite this article as: Gomez AM, Alfonso-Cristancho R, Orozco JJ, Lynch PM, Prieto D, Saunders R, et al. Beneficios clínicos y económicos de la terapia con bomba de insulina integrada a sistema de monitoreo continuo de glucosa en los pacientes diabéticos tipo 1 en Colombia. Endocrinol Nutr. 2016;63:466---474. ∗ Corresponding author. E-mail address: amgomezm5@gmail.com (A.M. Gomez). 2173-5093/© 2016 SEEN. Published by Elsevier Espa˜ na, S.L.U. All rights reserved.